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bjectives Our aim was to examine the prognostic importance of hemorrhagic and ischemic com-
lications after percutaneous coronary intervention (PCI) in unselected patients.
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pMI) have been associated with increased mortality. Whether similar associations exist among un-
elected PCI patients is unknown.
ethods We used data from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events)
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etween both in-hospital bleeding and pMI and 1-year mortality. Cardiac enzyme levels were as-
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f normal. Post-PCI bleeding was classiﬁed by Thrombolysis In Myocardial Infarction criteria.
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or evaluation. Rates of post-PCI bleeding and pMI were 3.0% and 7.1%, respectively; 1-year all-cause
ortality was 2.8%. After multivariable adjustment, both post-PCI bleeding (adjusted hazard ratio
HR]: 3.83, 95% conﬁdence interval: 2.48 to 5.90, p  0.001) and pMI (adjusted HR: 1.84, 95% conﬁ-
ence interval: 1.17 to 2.89, p  0.009) were independently associated with 1-year mortality. Time
eriod-speciﬁc analyses demonstrated that the adjusted HR for bleeding was similar for 30-day mor-
ality and mortality between 1 month and 1 year, while the adjusted HR for pMI was greater for 30-
ay mortality as compared with mortality between 1 month and 1 year.
onclusions Among unselected PCI patients, both post-PCI bleeding and pMI are independently
ssociated with increased 1-year mortality. Continued efforts to reduce these complications after PCI
re warranted. (J Am Coll Cardiol Intv 2009;2:1074–82) © 2009 by the American College of
ardiology Foundation
rom the *Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri; †Statistical
onsulting Unit, Boston University, Boston, Massachusetts; ‡Mayo Clinic, Rochester, Minnesota; §Vanderbilt University
edical Center, Nashville, Tennessee; University of Washington Medical Center, Seattle, Washington; ¶Beth Israel Deaconess
edical Center, Boston, Massachusetts; and the #Methodist DeBakey Heart Center, Houston, Texas. Dr. Marso has received
esearch grant support from The Medicines Company. Dr. Cohen has received research grant support from The Medicines
ompany, Schering-Plough, Eli Lilly, and Daichi Sankyo, and has been a consultant to Schering-Plough and Eli Lilly.anuscript received April 16, 2009; revised manuscript received July 17, 2009, accepted September 4, 2009.
B
i
b
t
n
i
t
T
s
p
b
d
d
m
(
i
h
d
w
(
e
p
t
i
u
S
q
c
t
p
M
T
b
w
o
s
a
t
p
t
p
m
S
b
o
b
i
s
b
(
a
w
t
D
c
c
a
C
t
a
l
(
b
a
d
o
m
a
m
t
w
p
S
e
w
p
C
n
t
B
T
f
b
j
i
w
h
b
t
b
S
m
C
a
F
K
a
p
P
a
i
h
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 1 , 2 0 0 9 Lindsey et al.
N O V E M B E R 2 0 0 9 : 1 0 7 4 – 8 2 Bleeding and MI After Contemporary PCI
1075oth periprocedural myocardial infarction (pMI) and bleed-
ng after percutaneous coronary intervention (PCI) have
een associated with increased short- and long-term mor-
ality (1–11). However, most studies evaluating the prog-
ostic significance of these events were based on random-
zed trial populations (1,4–8,10) or were published before
he current drug-eluting stent (DES) era (2,9,11–13).
herefore, a paucity of data exists regarding the prognostic
ignificance of post-PCI bleeding and pMI in unselected
atients undergoing PCI in the current era of antithrom-
otic and antiplatelet therapies. Although administrative
ata could potentially be used to address these issues, these
ata often suffer from incomplete or inconsistent ascertain-
ent of clinically relevant but “nonbillable” complications
14). In particular, assessment of pMI is poor in most admin-
strative datasets and even some clinical registries (15).
In addition, most studies evaluating post-PCI bleeding
ave only reported “major” bleeding (with a variety of
efinitions) as an independent predictor of mortality (6,7,9),
hile the impact of less severe bleeding events is less certain
5). Finally, until recently few studies have attempted to
xamine the independent effects of bleeding and pMI on
ost-PCI mortality in the same population. Consequently,
he relative prognostic significance of these 2 complications
n the post-PCI population is unknown. In this study, we
sed data from the EVENT (Evaluation of Drug-Eluting
tents and Ischemic Events) registry to identify the fre-
uency and severity of both bleeding and ischemic compli-
ations of PCI and to examine the relationship between
hese complications and 1-year mortality among unselected
atients.
ethods
he methods and population of the EVENT registry have
een described previously (16). Briefly, the EVENT registry
as a collaborative effort to assess the contemporary practice
f stenting by performing a prospective evaluation of un-
elected patients undergoing attempted implantation of an
pproved intracoronary stent at more than 50 PCI centers in
he U.S. Although enrollment in the registry was limited to
re-specified recruitment “waves,” specific efforts were made
o enroll patients consecutively during each enrollment
eriod (e.g., on pre-determined days of the week) to
inimize selection bias.
tudy population. The patient population for our study was
ased on all patients who underwent PCI in the first 3 waves
f the EVENT registry (n  7,587), which were enrolled
etween July 2004 and January 2006. Patients were excluded
f the primary indication for PCI was treatment of ST-
egment elevation myocardial infarction (STEMI) or if
aseline creatine kinase (CK)-MB levels were elevated
because of difficulty in ascertaining pMI in such individu-
ls) (Fig. 1). In addition, we excluded those subjects who were missing 1 candidate variable for the proposed mul-
ivariable models.
ata collection and end points. Data regarding patient
haracteristics, presentation, treatment, and outcomes were
ollected prospectively on standardized case report forms
nd submitted to the data coordinating center. CK and
K-MB levels were assessed at baseline (within 1 h before
he procedure) and every 8 h for a minimum of 2 samples
fter the procedure and assayed using each site’s clinical
aboratory and reference values. If a myocardial infarction
MI) was clinically suspected at a later point, additional
iomarkers were obtained as indicated.
Patients were contacted by telephone at 6 and 12 months
fter the index PCI. Events ascertained at follow-up included
eath, stent thrombosis, revascularization, and MI. All clinical
utcomes were adjudicated by 2 cardiologists blinded to treat-
ent factors and subsequent outcomes. The study protocol was
pproved by ethical review com-
ittees at all participating institu-
ions, and all patients provided
ritten informed consent before
articipation.
tudy deﬁnitions. The primary
nd point of the present analysis
as 1-year all-cause mortality.
MI was defined as elevation of
K-MB 3 the upper limit of
ormal (ULN) (as determined by
he local reference laboratory).
leeding was defined using the
hrombolysis In Myocardial In-
arction (TIMI) criteria (17). A
leeding event was defined as ma-
or if it was intracranial or if clin-
cally overt signs of hemorrhage
ere associated with a drop in
emoglobin of 5.0 g/dl. Minor
leeding was defined as clinically overt hemorrhage (including
hat visualized on imaging) associated with a fall in hemoglo-
in concentration of 3.0 to 5.0 g/dl.
tatistical methods. Continuous variables are described as
ean  SD and were compared using unpaired t tests.
ategorical variables are described as counts and percent-
ges and were compared using the chi-square test or the
isher exact test. One-year mortality was estimated by the
aplan-Meier method, and univariate associations were
ssessed by the log-rank test for both post-PCI bleeding and
MI.
To examine the independent associations between post-
CI bleeding, pMI, and 1-year mortality, multivariable-
djusted hazard ratios (HRs) and their 95% confidence
ntervals (CIs) were calculated using the Cox proportional
azards model. A sequentially saturated model was used
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
CK  creatine kinase
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
pMI  periprocedural
myocardial infarction
STEMI  ST-segment
elevation myocardial
infarction
ULN  upper limit of normalith adjustments for demographic variables (age, sex, body
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1076ass index); clinical variables (diabetes mellitus, hyperten-
ion, hypercholesterolemia, congestive heart failure, periph-
ral arterial disease, estimated glomerular filtration rate,
rior MI, prior coronary artery bypass grafting, acute
oronary syndrome [ACS] at presentation); and angio-
raphic and procedural variables (multivessel PCI, PCI of
aphenous vein graft, PCI of proximal left anterior descend-
ng coronary artery) in a hierarchical fashion. To reduce the
ikelihood of model overfitting, we restricted the number of
ovariates to 1 per 10 outcome events (18).
To further account for differences in baseline character-
stics between subjects with and without post-PCI bleeding
r pMI, we performed secondary analyses in which we used
ropensity score matching of patients with post-PCI bleed-
ng and pMI where 1 patient with an event (post-PCI
leeding or pMI) was matched with up to 4 without an
vent. The propensity scores for these analyses were calcu-
ated as predicted probabilities of each complication (post-
CI bleeding and pMI) based on logistic regression models
hat included the covariates listed in the preceding text.
atching required the propensity scores for patients with
nd without events to be within 0.01 (i.e., 1%). For the
ropensity-matched analyses, we used a conditional propor-
ional hazard model, stratified by quintile of the propensity
core.
Finally, to evaluate the prognostic impact of post-PCI
leeding and MI on short- (30 days) and longer- (between
0 days and 1-year) term mortality, we performed time
eriod-specific analyses using 2 time-dependent exposure
ariables with a change point of 30 days. We also tested for
Figure 1. Study Flow Diagram
Study ﬂow diagram illustrating the number and reason for exclusion. CK 
creatine kinase; STEMI  ST-segment elevation myocardial infarction;
ULN  upper limit of normal.he interaction between post-PCI bleeding and pMI with phe change point time variable to determine if there was a
ifference in their prognostic associations with short versus
onger-term mortality.
Probability values of 0.05 were considered to indicate
tatistical significance. All statistical analyses were per-
ormed using SAS version 9.1 (SAS Institute, Cary, North
arolina).
esults
atient population and in-hospital outcomes. Baseline char-
cteristics of the study population and index revasculariza-
ion procedures are described in Table 1. The patient
opulation was broadly representative of the general U.S.
opulation undergoing nonemergent PCI. The mean age
as 65  11 years, 68% were men, 35% had diabetes, and
3% were current smokers. The indication for PCI was an
CS (without STEMI) in 34% and stable coronary artery
isease in 60%. DES were used in 92%, and use of either
lycoprotein IIb/IIIa inhibitors or direct thrombin inhibi-
ors (mainly bivalirudin) was common. Among the 5,961
atients, the overall post-PCI bleeding rate was 3.0% (0.7%
IMI major and 2.3% TIMI minor), and the overall pMI
ate was 7.1% (3.5% with CK-MB values 3 to 5 ULN,
.1% with CK-MB values 5 to 10 ULN, and 1.5% with
K-MB values 10 ULN). The 1-year all-cause mortal-
ty rate was 2.8% (1.6% cardiac).
Patients with post-PCI bleeding were older, more likely
o be women, more likely to have diabetes, hypertension,
eart failure, peripheral arterial disease, to have renal insuf-
ciency (or be receiving chronic hemodialysis), more likely
o have undergone previous coronary artery bypass grafting,
nd more likely to have ACS at presentation. Among
ngiographic and procedural characteristics, those with
ost-PCI bleeding were more likely to have undergone PCI
f the left main coronary artery or a saphenous vein graft,
ultivessel PCI, and PCI of type C lesions. Use of heparin
lone and heparin  glycoprotein IIb/IIIa antagonists was
lightly higher among those with post-PCI bleeding, and
se of direct thrombin inhibitors was lower (Table 1).
Patients with pMI were less likely to have hypertension or
iabetes, and more likely to have renal insufficiency and
CS at presentation. There were no differences among the
roups with regard to age or sex. Among angiographic
haracteristics, those with pMI were more likely to have
ndergone PCI of the left anterior descending coronary
rtery or a saphenous vein graft, PCI of a type C lesion,
ultivessel PCI, and treatment of a bifurcation lesion. With
egard to procedural characteristics, individuals with a pMI
ad a greater number of stents implanted and longer total
tent lengths (Table 2).
ssociation between bleeding and mortality. Compared
ith those without post-PCI bleeding, patients with any
ost-PCI bleeding (combined TIMI major and minor) had
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1077Table 1. Demographic, Clinical, and Angiographic Characteristics in Subjects With and Without Post-PCI Bleeding
Overall
(n  5,961)
No Bleeding
(n  5,781)
Bleeding
(n  180)
p
Value
Clinical characteristics
Age (yrs) 64.7 11.4 64.6 11.4 70.4 10.7 0.001
Men (%) 67.5 68.3 43.9 0.001
Body mass index (kg/m2) 29.9 6.5 29.9 6.5 29.2 6.6 0.15
Diabetes mellitus (%) 35.4 35.1 45.0 0.006
Hypertension (%) 79.8 79.6 88.9 0.002
Hypercholesterolemia (%) 75.8 75.9 71.7 0.19
Current smoker (%) 22.7 22.9 15.0 0.01
Congestive heart failure (%) 10.5 10.0 28.3 0.001
Peripheral arterial disease (%) 10.4 9.9 25.0 0.001
Hemodialysis (%) 1.6 1.6 3.9 0.03
Previous MI (%) 32.0 31.6 43.3 0.001
Previous PCI (%) 38.9 39.1 32.8 0.09
Previous CABG (%) 23.0 22.7 32.2 0.003
GFR (ml/min)*
30 3.1 2.8 11.1 0.001
30–59 21.5 21.0 37.8
60 75.5 76.2 51.1
Indication for PCI (%)
Stable angina or positive stress test 59.2 59.8 41.2 0.001
Acute coronary syndrome 33.6 33.0 54.7
Other 7.1 7.2 4.1
Angiographic characteristics (%)
Lesion location
LMCA 2.1 2.0 6.1 0.001
LAD 41.2 41.1 43.3 0.55
LCX 26.1 26.0 27.8 0.59
RCA 35.5 35.7 31.1 0.21
SVG 8.7 8.5 14.4 0.006
Lesion complexity (worst)
A 10.3 10.4 6.7 0.004
B 66.3 66.5 59.4
C 23.4 23.1 33.9
Multivessel PCI 14.3 14.1 21.7 0.004
Bifurcation lesion 12.2 13.9 12.2 0.49
Procedural characteristics
Number of stents 1.6 0.9 1.6 0.9 1.8 1.1 0.02
Maximum stent diameter (mm) 3.1 1.0 3.1 0.6 3.1 1.0 0.80
Total stent length (mm) 24.2 13.6 23.0 11.4 24.3 13.7 0.25
Type of stent (%)
Drug-eluting stent 92.2 92.3 88.0 0.03
Bare-metal stent 7.8 7.7 12.0
Antithrombotic therapy (%)
Heparin alone 18.7 18.6 21.7 0.001
Heparin and GP IIb/IIIa inhibitor 33.6 33.2 43.3
Direct thrombin inhibitor 34.9 35.4 20.0
Other† 12.8 12.7 15.0
Therapeutic clopidogrel load (%) 40.1 39.9 43.9 0.29
Data are presented as mean  SD and percentages where appropriate. The p values are for the comparison of bleeding versus no bleeding.
*Calculated by the Cockcroft-Gault equation; †other includes low-molecular-weight heparin alone or in combination with glycoprotein (GP) IIb/IIIa
antagonists, GP IIb/IIIa antagonists alone, and various combinations (i.e., bivalirudin with GP IIb/IIIa antagonists).
CABG coronary artery bypass graft; GFR glomerular filtration rate; LAD left anterior descending; LCX left circumflex; LMCA left maincoronary artery; MImyocardial infarction; PCI percutaneous coronary intervention; RCA right coronary artery; SVG saphenous vein graft.
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1078Table 2. Demographic, Clinical, and Angiographic Characteristics in Subjects With and Without Periprocedural MI
No Periprocedural MI
(n  5,535)
Periprocedural MI
(n  426)
p
Value
Clinical characteristics
Age (yrs) 64.7 11.4 65.7 11.5 0.08
Men (%) 67.6 66.2 0.53
Body mass index (kg/m2) 30.0 6.6 28.7 5.5 0.001
Diabetes mellitus (%) 35.8 29.6 0.009
Hypertension (%) 80.3 73.7 0.001
Hypercholesterolemia (%) 76.0 72.5 0.10
Current smoker (%) 22.6 23.2 0.77
Congestive heart failure (%) 10.6 10.1 0.76
Peripheral arterial disease (%) 10.3 11.3 0.54
Hemodialysis (%) 1.7 0.5 0.05
Previous MI (%) 31.7 35.0 0.17
Previous PCI (%) 39.3 33.6 0.02
Previous CABG (%) 23.1 21.4 0.41
GFR (ml/min)
30 3.1 2.6 0.04
30–59 21.1 26.3
60 75.8 71.1
Indication for PCI (%)
Stable angina or positive stress test 59.7 52.9 0.005
Acute coronary syndrome 33.1 40.9
Other 7.2 6.1
Angiographic characteristics (%)
Lesion location
LMCA 2.0 3.3 0.08
LAD 40.8 45.8 0.04
LCX 25.8 29.3 0.11
RCA 35.7 33.1 0.28
SVG 8.5 11.3 0.05
Lesion complexity (worst)
A 10.6 6.4 0.001
B 66.9 58.6
C 22.5 35.0
Multivessel PCI 13.7 22.1 0.001
Bifurcation lesion 11.9 16.9 0.002
Procedural characteristics
Number of stents 1.6 0.9 2.2 1.2 0.001
Maximum stent diameter (mm) 3.1 1.1 3.1 0.5 0.23
Total stent length (mm) 23.7 13.3 30.6 16.5 0.001
Type of stent (%)
Drug-eluting stent 92.3 90.5 0.18
Bare-metal stent 7.7 9.5
Antithrombotic therapy (%)
Heparin alone 19.0 15.0 0.001
Heparin and GP IIb/IIIa inhibitor 33.3 37.3
Direct thrombin inhibitor 35.4 28.9
Other* 12.4 18.8
Therapeutic clopidogrel load (%) 40.1 39.2 0.71
Data are presented asmean SD and percentages where appropriate. *Other includes low-molecular-weight heparin alone or in combinationwith
GP IIb/IIIa antagonists, GP IIb/IIIa antagonists alone, and various combinations (i.e., bivalirudin with GP IIb/IIIa antagonists).Abbreviations as in Table 1.
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1079ncreased 1-year mortality (15.6% vs. 2.4%, p  0.001) (Fig.
A). When post-PCI bleeding events were stratified according
o the TIMI criteria, individuals who experienced TIMI major
leeding had the highest 1-year mortality (21.9%), while
atients with TIMI minor bleeding had intermediate 1-year
ortality (13.7%) (Fig. 2B). There were no significant differ-
nces in baseline demographic, clinical, or angiographic char-
cteristics among those with TIMI minor bleeding versus
IMI major bleeding (data not shown).
Before risk adjustment, post-PCI bleeding of any severity
as associated with increased risk for 1-year mortality (HR:
.83, 95% CI: 4.55 to 10.24; p 0.001). After multivariable
djustment, the impact of bleeding was attenuated substan-
ially; nonetheless, post-PCI bleeding of any severity re-
ained independently associated with mortality (adjusted
R: 3.83, 95% CI: 2.48 to 5.90; p  0.001) (Fig. 3). The
ssociation remained significant in propensity-matched
nalyses as well (HR: 3.60, 95% CI: 2.16 to 6.00; p 
.001). When bleeding severity was stratified by TIMI
riteria, both TIMI major bleeding (adjusted HR: 6.85,
5% CI: 3.37 to 13.89; p  0.001) and TIMI minor
Figure 2. 1-Year Mortality Among Patients With and Without Post-PCI
Bleeding
Kaplan-Meier curves demonstrating 1-year all-cause mortality among
patients with and without (A) post-percutaneous coronary intervention
(PCI) bleeding or (B) bleeding, stratiﬁed according to the Thrombolysis In
Myocardial Infarction major and minor bleeding criteria.leeding (adjusted HR: 3.12, 95% CI: 1.87 to 5.21; p .001) remained independently associated with increased
-year mortality.
ssociation between pMI and mortality. Patients who expe-
ienced a pMI had 1-year mortality that was approximately
wice that of patients without pMI (5.2% vs. 2.7%; p 
.002) (Fig. 4). Before risk adjustment, pMI was associated
ith an increased risk for 1-year mortality (HR: 2.00, 95%
I: 1.27 to 3.14; p  0.001). After multivariable adjust-
ent, the HR remained largely unchanged, and pMI
emained independently associated with increased mortality
adjusted HR: 1.84, 95% CI: 1.17 to 2.89; p 0.009) (Fig. 5).
Figure 3. Multivariable-Adjusted HRs for the Association Between
Post-PCI Bleeding and 1-Year Mortality
Adjusted hazard ratios (HRs) for the association between post-percutaneous
coronary intervention (PCI) bleeding and 1-year mortality. *Model 1:
adjusted for sociodemographic factors; †Model 2: adjusted for Model 1
covariates  clinical factors; ‡Fully adjusted: adjusted for all Model 2
covariates  angiographic and procedural factors  periprocedural myo-
cardial infarction. See Methods section for full list of model covariates.
Figure 4. 1-Year Mortality Among Patients With and Without
Periprocedural MI
Kaplan-Meier curves of 1-year post-percutaneous coronary intervention
mortality among patients with and without periprocedural myocardial
infarction (MI).
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1080imilar findings were noted in propensity-matched analyses
s well (adjusted HR: 1.82, 95% CI: 1.09 to 3.06; p 0.02).
hort- versus longer-term associations between complica-
ions and mortality. Time period-specific analyses demon-
trated that the association between post-PCI bleeding and
ortality was qualitatively similar for short-term (30-day)
adjusted HR: 3.92, 95% CI: 1.46 to 10.52; p  0.001) and
onger-term (30-day to 1-year) mortality (adjusted HR:
.79, 95% CI: 2.35 to 6.10; p  0.001). In contrast, the
ssociation between pMI and mortality was significant and
tronger for short-term (30-day) mortality (adjusted HR:
.89, 95% CI: 2.63 to 13.12; p  0.001) but was not
ignificant for longer-term mortality (30-day to 1-year)
adjusted HR: 1.25, 95% CI: 0.70 to 2.21; p  0.46). There
as a significant interaction between time and pMI indi-
ating a difference in the prognostic impact of these events
n short- versus longer-term mortality (p  0.003).
iscussion
n this study, we used data from 5,961 unselected PCI
atients treated between 2004 and 2006 to assess the
requency of both pMI and bleeding complications in
ontemporary practice and the association between these
vents and subsequent mortality. Despite numerous ad-
ances in PCI technique, devices, and adjunct pharmacol-
Figure 5. Multivariable-Adjusted HRs for the Association Between pMI
and 1-Year Mortality
Adjusted hazard ratios (HRs) for the association between periprocedural
myocardial infarction (pMI) and 1-year mortality. *Model 1: adjusted for
sociodemographic factors; †Model 2: adjusted for Model 1 covariates 
clinical factors; ‡Fully adjusted: adjusted for all Model 2 covariates  angio-
graphic and procedural factors  post-percutaneous coronary intervention
bleeding. See Methods section for full list of model covariates.gy over the past 2 decades (19), we found that with careful eurveillance (including routine monitoring of post-
rocedure cardiac enzymes) both of these events remain
elatively common. pMI was observed in 7.1% of patients,
hile bleeding complications were noted in 3.0%. The rate
f pMI in our unselected population is virtually identical to
he 8% rate recently reported among patients who under-
ent routine assessment of post-procedure cardiac enzymes
n the ACC–NCDR (American College of Cardiology–
ational Cardiovascular Data Registry) (15) and serves to
ighlight the importance of such surveillance for both
onitoring and improving the quality of PCI procedures.
In addition to their frequency, we found that both
leeding (of any severity) and pMI were independently
ssociated with 1-year, all-cause mortality among our “real-
orld” PCI population. In time-dependent analyses, how-
ver, the patterns of association differed somewhat between
hese 2 complications. For post-PCI bleeding, the adjusted
R for 30-day mortality was qualitatively similar to that for
ortality between 1 month and 1 year. In contrast, for pMI,
he association with mortality was strongest during the first
0 days and not significant for events beyond this time
oint.
Several previous studies have demonstrated an indepen-
ent association between bleeding and subsequent mortality
fter PCI (5–7,11). For example, Ndrepepa et al. (5)
eported pooled data from the ISAR (Intracoronary Stent-
ng and Antithrombotic Regimen) trials that demonstrated
hat bleeding of any severity after PCI was independently
ssociated with 1-year mortality. Of note, the rates of
leeding after PCI (4%) were similar to those reported in
he current study (3%) as was the point estimate for the
elative risk of mortality. In addition, results from the
CUITY (Acute Catheterization and Urgent Intervention
riage Strategy) trial (6), which demonstrated that major
leeding was associated with increased mortality, also sup-
ort our findings. Similar findings have been noted in ACS
atients as well, independent of the performance of PCI
6,8,10). Despite the consistency of these findings, however,
mportant questions remain regarding their generalizability
s well as the causal nature of the association (20).
Our study adds to the available data by extending these
revious observations—which were derived largely from
linical trial populations—to a large, unselected population
ndergoing PCI using contemporary devices and pharma-
ologic regimens including DES in 90% and pre-PCI
lopidogrel loading in 40% of patients. Moreover, our
tudy is one of the first to demonstrate a graded relationship
etween the severity of bleeding and long-term mortality in
PCI population—findings that were first described by Rao
t al. (10) in an analysis of clinical trial participants with
CS. Although other explanations remain possible (e.g.,
nmeasured confounding), the finding of a “dose-response
urve” in the bleeding-mortality association provides further
vidence of a potential causal relationship (21).
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1081The prognostic importance of pMI after PCI has been
eported in prior studies as well (1–5,12,13,22). Many of
hese studies were summarized in a recent meta-analysis in
hich Ioannidis et al. (3) found that any increase in
K-MB after PCI, especially a 3-fold CK-MB elevation,
as associated with a significant increase in the subsequent
isk of death. Similar to the literature on post-PCI bleeding,
owever, the vast majority of these studies pre-date the
urrent era of DES and prolonged dual antiplatelet era.
hus, our study serves to re-emphasize the importance of
schemic complications as a key prognostic factor after PCI
n contemporary practice.
In addition to demonstrating its importance as a prog-
ostic factor after PCI, our study provides several novel
nsights into the relative magnitude and timing of the
rognostic impact of bleeding and ischemic complications
fter PCI. In particular, we found that as a predictive factor,
he association between bleeding (with an overall incidence
f 3% in our population) and 1-year mortality was about
wice as strong as for pMI (with an incidence of 6%).
hese findings suggest that the population-attributable risks
re similar for these 2 complications and that a similarly
ffective effort to further reduce these complications is likely
o yield comparable benefits in terms of 1-year mortality.
These extrapolations are based on the assumption that
he observed associations with mortality are of a causal
ature—an assumption that remains controversial. For
MI, our observation that the association is strongest in the
rst 30 days after PCI and not significant after 30 days is
easonably consistent with a causal chain. For bleeding,
owever, the fact that the association is similar in both the
rst month and in the subsequent 11 months may reflect
ither unmeasured confounding or a mechanism of mortal-
ty that relates to latent effects of bleeding on inflammation
r the immune response (20,23).
The results of the current study provide further evidence
hat both bleeding and pMI after PCI continue to be
ommon, and future efforts should be aimed at a reduction
f these events. This is a difficult proposition because use of
ore potent antiplatelet and antithrombotic drugs tends to
educe ischemic complications after PCI but typically results
n increased bleeding rates (24–27). Recent data do suggest
hat some antithrombotic drugs may be preferable to others
ecause of reduced major bleeding rates after PCI and that,
n certain settings, it may even be possible to reduce
leeding without increasing ischemic events (28,29). In
ddition, the use of radial artery access, as opposed to
emoral artery access, appears to reduce the rate of access site
leeding after PCI, suggesting a further therapeutic option
or improving both short- and long-term outcomes in PCI
atients (30,31). Other strategies to potentially reduce
ost-PCI bleeding events include use of smaller vascular
ccess sheaths (31), fluoroscopy-guided arterial puncture
32), judicious use of vascular access closure devices (33), end avoidance of excessively high activated clotting times
uring PCI (31).
tudy limitations. First, despite our best efforts to adjust for
otential confounders by using multivariable models and
ropensity matching, given the observational nature of the
resent study, it is likely that unmeasured confounders could
ave contributed to the observed differences in mortality
mong subjects with post-PCI bleeding and pMI. Second,
t is conceivable that the rates of pMI and post-PCI
leeding were under-reported. However, in the case of pMI,
he fact that CK-MB levels were assessed both before and
fter PCI in 97% of study subjects makes this possibility
elatively unlikely. However, the EVENT registry did not
andate post-PCI assessment of hemoglobin in all patients.
hus, it is possible that some clinically silent bleeding events
ent undetected. Moreover, post-PCI bleeding was only
racked during the index hospitalization.
Third, our assessment of mortality was restricted to
-year events. Thus, the prognostic impact of periproce-
ural complications on longer-term mortality cannot be
ssessed. Other investigators have reported that the prog-
ostic importance of pMI extends beyond 1 year (1,2,13),
ut to our knowledge no long-term data (1 year) have
een reported for post-PCI bleeding and mortality. Fourth,
e excluded STEMI patients from the current analysis;
onsequently, our results apply only to patients undergoing
ither nonemergent PCI in either the elective or unstable
ngina/NSTEMI setting. Of note, however, recent unpub-
ished data from the HORIZONS-AMI (Harmonizing
utcomes with Revascularization and Stents in Acute
yocardial Infarction) study have shown that major bleed-
ng after primary PCI is strongly associated with an in-
reased risk for mortality at 30 days (34). Finally, there was
eterogeneous use of antithrombin therapy in the EVENT
egistry; however, adjustment for the type of antithrombin
herapy used did not appreciably alter the point estimates for
ortality. Furthermore, the observed differences in utiliza-
ion rates of antithrombin therapies are likely due to a
ariety of unmeasured factors; consequently, no conclusions
hould be drawn regarding the superiority of 1 antithrombin
reatment regimen with regard to post-PCI bleeding or
MI.
onclusions
n this large, unselected population of patients undergoing
CI with DES and contemporary antithrombotic therapy,
oth pMI and bleeding remain frequent complications that
re independently associated with increased long-term mor-
ality. Although the causal nature of these associations
emains speculative, these findings suggest that continued
fforts to reduce these complications are warranted.
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